Urologix Products Featured in Cost-Effectiveness Research to be Presented at Upcoming Industry Meeting in New Orleans

MINNEAPOLIS, May 12, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced an upcoming presentation at the American Urological Association (AUA) 2015 annual meeting to be held May 15-18, 2015 in New Orleans, LA.

The podium presentation (Abstract #PD16-09) “Healthcare Costs for Office Based Benign Prostatic Hyperplasia Therapies” was submitted by Craig Smith, MD, FAAP, FACS, DuPage Medical Group, Chicago, IL and Robert G. Pugach, MD, Medical Director, Pacific Coast Urology, Huntington Beach, CA. The presentation will be given Saturday, May 16th in the Benign Prostatic Hyperplasia: Medical & Non-Surgical Therapy podium session between 1:00pm – 3:00pm CDT in Room 215-216, at the New Orleans Morial Convention Center.

“We are excited that the AUA accepted this abstract for a podium presentation. Treatment options, like ours, that provide both low costs and good clinical outcomes are of growing importance to urologists and patients. They both have to navigate a changing healthcare system where they are shouldering more financial risk for the provision of healthcare. With alternative payment structures like ACOs and high deductible insurance coverage, people need to understand what they are paying for,” stated Greg Fluet, CEO of Urologix.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix's Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate, destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.

If you’d like more information on this topic, please contact Scott Madson at (763) 475-1400 or investor-relations@urologix.com. To learn more about Urologix and its products and services, visit their website at www.urologix.com.

The Urologix, Inc. logo is available at www.urologix.com/clinicians/resource-library.php



CONTACTS: Urologix Media Contact Susan Overby (763) 745-1540 soverby@urologix.com Urologix Investor Relations Contact Scott Madson (763) 475-1400 smadson@urologix.com

Source:Urologix, Inc.